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We previously demonstrated a characteristically high sensitivity of pancreatic cancer cells to interferon alpha (IFN-a) gene transfer,
which induced a more prominent growth suppression and cell death in pancreatic cancer cells than in other types of cancers and
normal cells. The IFN-a protein can exhibit both direct cytotoxicity and indirect immunological antitumour activity. Here, we
dissected and examined the two mechanisms, taking advantage of the fact that IFN-a did not show any cross-species activity in its
in vivo effect. When a human IFN-a adenovirus was injected into subcutaneous xenografts of human pancreatic cancer cells in nude
mice, tumour growth was significantly suppressed due to cell death in an adenoviral dose-dependent manner. The IFN-a protein
concentration was markedly increased in the injected subcutaneous tumour, but leakage of the potent cytokine into the systemic
blood circulation was minimal. When a mouse IFN-a adenovirus was injected into the same subcutaneous tumour system, all mice
showed significant tumour inhibition, an effect that was dependent on the indirect antitumour activities of IFN-a, notably a stimulation
of natural killer cells. Moreover, in this case, tumour regression was observed not only for the injected subcutaneous tumours but also
for the untreated tumours at distant sites. This study suggested that a local IFN-a gene therapy is a promising therapeutic strategy for
pancreatic cancer, due to its dual mechanisms of antitumour activities and lack of significant toxicity.
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Adenocarcinoma of the pancreas is, at present, one of the most
intractable cancers, and despite recent advances of therapeutic and
diagnostic modalities, the prognosis remains unimproved (Haller,
2003; Safioleas and Moulakakis, 2004). Patients with pancreatic
cancer often succumb to local recurrence or metastatic spread
(Akerele et al, 2003; Safioleas and Moulakakis, 2004). One major
reason for the poor prognosis is that the cancer cells, even when
they are small, have a high propensity to infiltrate to the
surrounding tissues and metastasise to distant organs. Therefore,
it is often necessary to consider pancreatic cancer as a systemic
disease, and new therapeutic strategies that effectively target this
cancer in vivo, are required (Okusaka and Kosuge, 2004; Yoshida
et al, 2004).
The interferon alpha (IFN-a) protein is a cytokine with multiple
biological activities that include antiviral activity, regulation of cell
proliferation and differentiation and immunomodulation (Pfeffer
et al, 1998). The cytokine has been used worldwide for the
treatment of a variety of cancers including some haematological
malignancies (hairy cell leukaemia, chronic myeloid leukaemia,
some B- and T-cell lymphoma) and certain solid tumours such
as melanoma, renal carcinoma and Kaposi’s sarcoma (Gutterman,
1994; Pfeffer et al, 1998). However, clinical experiences with IFN
protein therapy of other cancers, especially in the treatment of
many solid tumours, have generally not been encouraging (Pfeffer
et al, 1998). In the conventional regimen of IFN clinical trials, the
recombinant IFN-a protein is systemically administrated through
subcutaneous, intravenous or intramuscular routes. However,
pharmacokinetic studies have indicated that the half-life of the
IFN-a protein is 3h in the blood circulation and only 0.01% of
subcutaneously injected IFN-a can reach the target sites (Salmon
et al, 1996; Suzuki et al, 2003), indicating that IFN-a protein
delivery might be insufficient and/or at an unsustainable level in
the tumour site. This may be the major reason why the previous
trials based on the conventional IFN-a therapy failed to show an
adequate antitumour effect. By contrast, improved therapeutic
effect and safety are expected for IFN-a gene transfer, because it
allows an increased and sustained local concentration of this
cytokine in the target sites while minimising unnecessary systemic
distribution (Suzuki et al, 2003; Hatanaka et al, 2004). In fact, it
has been reported that direct IFN-a gene transfer into tumours
suppressed growth of various cancers such as breast cancer,
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carcinoma and leukaemia (Zhang et al, 1996; Coleman et al, 1998;
Hottiger et al, 1999; Iqbal Ahmed et al, 2001). Although no study of
IFN-a gene transfer against pancreatic cancer had been reported,
we recently found that the expression of IFN-a effectively induced
growth suppression and cell death in pancreatic cancer cells, an
effect that appeared to be more prominent than in other types of
cancers and normal cells (Hatanaka et al, 2004).
In addition to its direct cytotoxicity, IFNs can also exhibit an
indirect antitumour effect through immune stimulations. They
induce a major histocompatibility complex class I expression,
cause an increase in cytotoxic T-lymphocyte activity, enhance the
generation of T helper cells and activate macrophages and natural
killer (NK) cells (Chawla-Sarkar et al, 2003). In this study, to
explore the immunological antitumour activity of IFN-a gene
therapy, we tested mouse IFN-a gene delivery into human
pancreatic cancer xenograft tumours in nude mice. Although the
mouse IFN-a did not show a direct antiproliferative effect against
human pancreatic cancer cells in vitro, the mouse IFN-a gene
transduction into pancreatic cancer xenografts showed significant
inhibition of tumour growth, which was attributed to an IFN-a-
induced stimulation of NK cells. This study together with our
previous report showing a characteristically high sensitivity of
pancreatic cancer cells to the direct cytotoxicity of IFN-a transgene
expression (Hatanaka et al, 2004) suggests that IFN-a gene therapy
is a promising therapeutic strategy for pancreatic cancer, due to its
dual mechanisms of antitumour activities.
MATERIALS AND METHODS
Cell lines and recombinant adenovirus vectors
Human pancreatic cancer cell lines (Panc-1, AsPC-1, BxPC-3 and
MIAPaCa-2) and murine renal cancer cell line (Renca) were used
in this study. All cell lines were obtained from American Tissue
Culture Collection (Rockville, MD, USA), and were maintained in
an RPMI-1640 medium with 10% foetal bovine serum. The
recombinant adenovirus vectors expressing human IFN-a2a
(AxCA-IFN), mouse IFN-a (AdCA-mIFN), enhanced green fluo-
rescein protein (AdCA-EGFP) and alkaline phosphatase cDNA
(AdCA-AP) were prepared as described (Aoki et al, 1999; Nakano
et al, 2001; Suzuki et al, 2003). A cesium chloride-purified virus
was desalted using a sterile Bio-Gel P-6 DG chromatography
column (Econopac DG 10, BioRad, Hercules, CA, USA) and diluted
for storage in a 13% glycerol/PBS solution. All viral preparations
were confirmed to be free of E1
þ adenovirus by PCR assay (Zhang
et al, 1995).
In vitro growth analysis
The AsPC-1 and Renca cells were seeded at 2 10
3well
 1 in
96-well plates and infected with AxCA-IFN, AdCA-mIFN or AdCA-
EGFP at an MOI of 10, 30 and 100. The cell numbers were assessed
by a colorimetric cell viability assay using a water-soluble
tetrazolium salt (Tetracolor One; Seikagaku Corp., Tokyo, Japan)
5 days after the infection. The absorbance was determined by
spectrophotometry using a wavelength of 450nm with 595nm as
a reference. The assays (carried out in eight wells) were repeated a
minimum of two times and the mean7standard deviation (s.d.)
was plotted. The data were expressed as the relative cell number
(OD450 of AxCA-IFN- or AdCA-mIFN-infected cells/OD450 of
AdCA-EGFP-infected cells).
Animal model
Female, 7- to 8-week-old BALB/c nude mice were obtained from
Charles River Japan (Kanagawa, Japan), and kept in a specific
pathogen-free environment. Among the cell lines used in this
study, we chose AsPC-1 for an in vivo gene transfer model, because
the cells rapidly form a tumour when inoculated in the
subcutaneous or peritoneal space of nude mice. For the direct
intratumoral treatment of subcutaneous tumours, AsPC-1 cell
suspensions (50mlo f5  10
6 cells) were injected subcutaneously
into the left leg. When the tumour mass was established (B0.5cm
in diameter), 50ml of a viral solution was injected into the tumour
with a 29-G hypodermic needle, and the animals were observed
for tumour growth. The short (r) and long (l) diameters of the
tumours were measured and the tumour volume of each was
calculated as r
2l/2. Tumour sizes (mean7s.e.m. (standard error of
mean)) were measured on the days indicated. For the distant
metastasis treatment, 5 10
6 of AsPC-1 cells were injected
subcutaneously into the left leg and 1 10
6 of AsPC-1 cells were
simultaneously injected into the right leg. When the tumour mass
on the left leg was established (B0.5cm in diameter), 50ml
(1.0 10
8PFU) of the viral solution was injected once into the
subcutaneous tumour on the left leg, and the animals were
observed for tumour growth on both legs. For the peritoneal
dissemination treatment, 5 10
6 cells of AsPC-1 cell suspensions
were injected subcutaneously into the left leg. When the tumour
mass on the left leg was established, 1 10
6 or 5 10
6 cells of
AsPC-1 cell suspensions were injected into the peritoneal cavity.
After 1 day, 1.0 10
8PFU of the viral solution was injected once
into the subcutaneous tumour, and the animals were observed
for survival. For NK cell depletion experiments, we started the
intraperitoneal injection (50ml) of anti-asialo GM1 antibody
(30mgml
 1: Wako Chemicals USA Inc., Richmond, VA, USA) 2
days before the vector administration and the treatment was
repeated every 2–3 days for five times. Animal protocols were
reviewed and approved by the Institutional Animal Core and Use
Committee of the National Cancer Center Research Institute.
RT–PCR and flow cytometric analyses of NKG2D ligands
PCR amplification of five known genes of NKG2D ligands (MICA,
MICB, ULBP-1, ULBP-2 and ULBP-3) and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was carried out using total
RNA from the cells in a 50ml of PCR mixture containing 1.5mM
MgCl2, 0.2mM dNTPs, 1U of recombinant Taq DNA polymerase
and the following primer set: MICA upstream (50-TTCCTGCT
TCTGGCTGGCATC-30) and downstream primers (50-GCAGAAAC
ATGGAATGTCTGCCAA-30); MICB upstream (50-CTGCTGTTTC
TGGCCGTCGC-30) and downstream primers (50-GAAACATATG
GAAAGTCTGTCCG-30); ULBP-1 upstream (50-CGCCTTCCTTCTG
TGCCTCC-30) and downstream primers (50-AGATGATGAGAAGG
CTCCAGGG-30); ULBP-2 upstream (50-AAGATCCTTCTGTGC
CTCCCG-30) and downstream primers (50-GGATGATGAGGAGG
CAGCAAAG-30); ULBP-3 upstream (50-GCGATCCTTCCGCG
CCTC-30) and downstream primers (50-CAGGGTTTCTCGCTGAG
GGAC-30); and GAPDH upstream (50-TGAAGGTCGGAGTCAACG
GATTTGGT-30) and downstream primers (50-CATGTGGGCCAT
GAGGTCCACCAC-30). In total, 35 cycles (GAPDH: 27 cycles) of
the PCR were carried out at 941C for 30s, 681C (MICB: 651C,
GAPDH: 601C) for 1min and 721C for 1min. The PCR products
were electrophoresed on a 2% agarose gel. Daudi (human Burkitt’s
lymphoma) and K562 (human chronic myelogenous leukaemia)
cells were used as negative and positive controls, respectively,
for NKG2D ligands. The surface expression of MICA and MICB
was then evaluated by flow cytometry. Cells (5 10
5) were
incubated at 41C for 30min with phycoerythrin-conjugated mouse
anti-human MICA/B monoclonal antibody (6D4; IgG, BD Bios-
ciences Pharmingen, San Jose, CA, USA) or isotype control
antibody (IgG), and then washed twice with PBS containing 2%
BSA and 0.05% NaN3 and fixed with 2% paraformaldehyde
solution. Flow cytometry was carried out using a FACScan system
(Becton Dickinson).
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To determine NK cell activity, BALB/c nude mice were killed 14
days after the administration of the vector. The spleen from each
animal was pressed through a nylon mesh and the cells were
suspended in DMEM containing 2.5mM EDTA and 3Uml
 1 of
heparin. The suspension was then washed twice with PBS, and
incubated with anti-NK cell antibody (DX5)-coated magnetic
microbeads (Miltenyi Biotec, Auburn, CA, USA) and passed
through a separation column to isolate the NK cells. NK cell
activity was determined using a chromium release assay described
previously (Tada et al, 2001). Briefly, 1 10
6 YAC-1 mouse
lymphoma cells (American Tissue Culture Collection) were
radiolabelled with 3.7Mbq of sodium chromate (
51Cr) (Amersham
Pharmacia Biotech, Piscataway, NJ, USA) in 500ml of RPMI-1640
at 371C for 2h. The cells were then washed twice with PBS and
diluted to 1 10
4 cells100ml
 1. Effector cells (NK cells) were
added at various effector/target ratios, and a final volume of 100ml
was added to the wells of a U-shaped 96-well plate. The reaction
was incubated at 371C for 4h. The 96-well plate was then
centrifuged, and the
51Cr release from 100ml of supernatant was
counted in a liquid scintillation counter. The percentage of
cytotoxicity was determined by the formula: (experimental
release spontaneous release/maximum release spontaneous
release) 100.
Histology
At 5 days after the injection of 1.0 10
8PFU of viral solutions
(AxCA-IFN, AdCA-mIFN and AdCA-AP), the mice were killed and
subcutaneous tumours were collected. The tumours were fixed
with formalin, and sections were stained with haematoxylin–eosin
or processed for immunohistochemistry with anti-asialo GM1
antibody (Wako Chemicals USA Inc.) and the terminal deoxy-
nucleotidyltransferase-mediated dUTP-digoxigenin nick-end-label-
ling (TUNEL) assay (ApopTag in situ apoptosis detection kit;
Intergen Company, Purchase, NY, USA). For microvessel detec-
tion, the fresh tumour samples were embedded in OCT compound
(Sakura Finetechnical Co., Tokyo, Japan) and sections were fixed
with 4% paraformaldehyde and then processed for immuno-
histochemistry with anti-mouse CD31 antibody (MEC13.3; BD
Biosciences Pharmingen). Immunostaining was performed using
the streptavidin–biotin–peroxidase complex techniques (Nichirei,
Tokyo, Japan). Parallel negative controls without primary anti-
bodies were run in all cases. The sections were counter-stained
with methylgreen. Microvessel areas were quantified by counting
of hotspots in sections, and 10 representative fields for each
tumour were counted.
Statistical analysis
Comparative analysis of in vivo tumour volume and in vitro cell
proliferation was performed by the Student’s t-test; mouse survival
was analysed by Kaplan–Meier survival plot followed by a log-
rank (Mantel–Cox) test. Differences were considered statistically
significant when P-value was o0.05.
RESULTS
Direct antitumour effect of human IFN-a gene
transduction into AsPC-1 tumours
We previously reported that an intratumoral injection of an
adenoviral vector expressing the human IFN-a gene, AxCA-IFN
(2.5 10
8PFU), effectively suppressed the growth of nude mouse
subcutaneous tumours of the AsPC-1 human pancreatic cancer
cells (Hatanaka et al, 2004). In this study, the superior antitumour
effect of the IFN-a gene therapy over the recombinant IFN-a
protein therapy was evaluated between the single injection of
1.0 10
8PFU of AxCA-IFN and 3 10
5IUg
 1 of recombinant
IFN-a protein, which corresponds to the top level achieved by the
1.0 10
8PFU of AxCA-IFN infection as shown in Figure 2. The
injection of AxCA-IFN showed remarkable tumour suppressive
effects in a dose-dependent manner, whereas recombinant IFN-a
protein therapy failed to produce a significant therapeutic
response (Figure 1), suggesting that an antitumour effect needs a
sustained and efficient local expression of IFN-a.
High IFN-a expression in subcutaneous tumour tissues
following intratumoral injection of AxCA-IFN with little
leakage into serum
To determine the kinetics of IFN-a expression after intratumoral
injection of AxCA-IFN, the IFN-a levels were measured in the
subcutaneous tumour and serum. As shown in Figure 2, the peak
levels in the tumour tissue were observed 3 days after the injection
and the expression continued for more than 10 days. Although the
injection of 2.5 10
8PFU of AdCA-AP showed a slight expression
of IFN-a at day 1, which may be a naı ¨ve reaction in response to
viral infection, the IFN-a expression returned to the base line
(o300IUg
 1) by day 9. The subcutaneous tumour showed
approximately 100–1000-fold higher IFN-a levels than the serum
did (Figure 2), confirming a markedly increased IFN-a concentra-
tion in the subcutaneous tumour with little leakage into the
serum (Hatanaka et al, 2004). After the intratumoral injection of
recombinant IFN-a protein (3 10
5IUg
 1), the concentration of
IFN-a was 6097130IUg
 1 at day 1 and returned to the base line
by day 3, which indicated the injected recombinant IFN-a protein
was rapidly degraded in the tumour.
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Figure 1 Direct antitumour effect of human IFN-a gene transduction
into AsPC-1 subcutaneous tumours. When the AsPC-1 subcutaneous
tumour was established on the left leg, the tumour was injected once with
2.5, 1.0 or 0.25 10
8PFU of AxCA-IFN, 2.5 10
8PFU of AdCA-AP or
3 10
5IUg
 1 of recombinant IFN-a protein (n¼6). Tumour size in each
mouse was plotted on the days indicated. *Po0.05 for tumours treated
with AxCA-IFN at 0.25 10
8PFU vs treated with AdCA-AP at
2.5 10
8PFU, **Po0.05 for tumours treated with AxCA-IFN at
0.25 10
8PFU vs treated at 1.0 10
8PFU, ***Po0.01 for tumours
treated with AxCA-IFN at 1.0 10
8PFU vs treated at 2.5 10
8PFU.
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Peritoneal dissemination is an often fatal end-stage manifestation
of pancreatic cancer in the clinical setting. To test the in vivo
antitumour effect against peritoneal dissemination, 5 10
6 of
AsPC-1 cells were inoculated into the peritoneal cavity of nude
mice, and 3 days later, the AxCA-IFN was injected intraperitone-
ally. Within 42 days after the adenovirus injection, all the control
AdCA-AP-injected mice died of peritoneal dissemination that
includes tumour formations on the mesentery, pancreas and
hepatic hilus. By contrast, the AxCA-IFN-treated group showed a
significant suppression of AsPC-1 cell growth in the peritoneal
cavity, allowing all the mice to survive more than 100 days
(Figure 3).
No cross-species activity in the antiproliferative effect of
IFN-a
To explore the immunological antitumour effect of IFN-a gene
therapy, we transduced the mouse IFN-a gene into human
pancreatic cancer xenografts in nude mice. First, the lack of
cross-species activity of IFN-a was confirmed by infecting human
pancreatic cancer (AsPC-1) and mouse renal cancer (Renca) cells
in vitro with a human or mouse IFN-a adenovirus. The infection
with AxCA-IFN showed significant growth suppression of AsPC-1
cells but not Renca cells. Conversely, the infection with AdCA-
mIFN resulted in marked growth retardation in Renca cells,
whereas its growth suppressive effect was not significant in AsPC-1
cells (Figure 4). In our previous report, IFN-a secreted into the
medium appeared to account for most, if not all, of the growth
suppression (Hatanaka et al, 2004).
Expression of NKG2D ligands in human pancreatic cancer
cells
NK cells are an important element of the innate immune system as
they are capable of killing tumour cells. The cytotoxic activity of
NK cells is enhanced by IFN-a/b through TRAIL (tumour necrosis
factor-related apoptosis-inducing ligand) gene induction (Sato
et al, 2001). NKG2D is one of the activating receptors on NK
cells, and a number of NKG2D ligands, such as MICA and MICB
(major histocompatibility complex class I chain-related) and ULBP
(UL16-binding proteins), have been identified (Groh et al, 1999;
Bahram, 2000; Kubin et al, 2001; Stephens, 2001; Raulet, 2003;
Yokoyama and Plougastel, 2003). It is known that the expression
of NKG2D ligands is upregulated in transformed cells, and that
the human NKG2D ligands can bind to mouse NKG2D, leading to
the activation of mouse NK cells (Kubin et al, 2001). To examine
whether the pancreatic cancer cells express the ligands, RT–PCR
and flow cytometric analyses were performed in four cell lines
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Figure 2 IFN-a concentration in the subcutaneous tumour and the serum after a single intratumoral injection of AxCA-IFN at various doses. IFN-a was
measured by enzyme-linked immunosorbant assay (Immunotech, Marseille Cedex, France) (n¼4).
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Figure 3 Treatment of peritoneal dissemination by the intraperitoneal
injection of AxCA-IFN. At 3 days after the intraperitoneal injection of
AsPC-1 cells (2 10
6 cells), 2.5 10
8PFU of AxCA-IFN (n¼5) or AdCA-
AP (n¼5) was intraperitoneally injected, and animals were observed for
survival. *Po0.01 for survival rates of mice treated with AxCA-IFN vs
treated with AdCA-AP.
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Figure 4 Lack of cross-species activity of human and mouse IFN-a gene
transfer. AsPC-1 and Renca cells were infected with AxCA-IFN, AdCA-
mIFN or AdCA-EGFP at an MOI of 10, 30 and 100. Cell growth was
determined by cell proliferation assay 5 days after the infection.
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all the pancreatic cancer cells examined expressed several kinds of
NKG2D ligands, suggesting that the cancer cells are effective
targets of NK cells.
Immunological antitumour effect of mouse IFN-a gene
transduction into AsPC-1 tumours
We next examined whether mouse IFN-a gene therapy leads to
regression of the human AsPC-1 xenograft tumours in nude mice.
We injected subcutaneous AsPC-1 tumours with AdCA-mIFN,
AxCA-IFN or AdCA-AP at a dose of 1.0 10
8PFU. Although
AxCA-IFN effectively suppressed tumour growth as shown in
our previous study (Hatanaka et al, 2004) and Figure 1, complete
tumour regression was observed in only one of six mice, and in the
particular experiment described here, one of the six mice failed to
respond to AxCA-IFN (Figure 6A, middle panel). AdCA-mIFN
caused complete regression in four of the six mice, and the
remaining two showed a significant growth retardation (Figure 6A,
left panel). There was no pathological change in major organs such
as the brain, lung, heart, liver, spleen, pancreas, kidney, stomach,
intestine, ovary and skeletal muscle of the vector-infected mice
(data not shown).
To confirm that mouse IFN-a gene delivery enhanced NK cell
activity, we collected splenocytes from the mice that received
intratumoral AdCA-mIFN injection and examined the NK cell
function. Increased NK cytolysis was observed in these mice
compared with the AxCA-IFN- or AxCA-AP-injected mice
(Figure 6B). Histological analysis of AdCA-mIFN-injected tumours
revealed infiltration of many monocytic cells, which were stained
with anti-asialo GM1 antibody, whereas AxCA-IFN-injected mice
also showed massive cell death but rare infiltration of monocytic
cells (Figure 7). TUNEL assay of AxCA-IFN- or AdCA-mIFN-
injected tumours revealed marked apoptosis induction (Figure 7).
An immunohistochemical staining with anti-murine CD31 anti-
body revealed a significantly decreased microvessel density in the
IFN-a gene-transduced AsPC-1 subcutaneous tumour models
(Figure 7); 10 representative fields under a microscope showed
121, 13 and 44 microvessel counts for the tumours injected with
AdCA-AP, AxCA-IFN and AdCA-mIFN, respectively. However,
it was not determined whether the loss of vessels was indirectly
caused by the marked cell death or directly caused by the
antiangiogenetic activity of IFN-a.
Pretreatment with an anti-asialo GM1 antibody to purge NK
cells reduced the antitumour effect of AdCA-mIFN (Figure 8A,
left panel) significantly, suggesting that mouse IFN-a expression
induced the activation of NK cells, which play a major role in the
antitumour effect of AdCA-mIFN.
No significant systemic toxicity after intratumoral
injection of AdCA-mIFN
To characterise the potential toxicity of local IFN-a gene therapy,
different doses of AdCA-mIFN were injected into the AsPC-1
subcutaneous tumours, and the animals were killed 5 or 11 days
later to evaluate serum enzyme values and histology of major
organs. All treated mice looked healthy during the course of the
experiment. Although a mild elevation of the hepatic enzymes
(AST and ALT) was observed at day 5 only when a relatively high
dose (2.5 10
8PFU) of IFN-a adenovirus was injected into the
tumours (Table 1), their values returned to a normal range at day
11. Other biochemical markers (albumin, alkaline phosphatase,
BUN, creatinin) were within normal limits, and there were no
pathological changes in major organs in all of the treated animals,
suggesting that systemic toxicity of local IFN-a gene therapy is
minimal.
Suppression of tumours at distant sites by intratumoral
injection of AdCA-mIFN
We then tested whether mouse IFN-a gene transduction has an
effect on untreated tumours at distant sites. We injected AsPC-1
cells into both legs, and when the tumour diameter reached about
5mm, 1 10
8PFU of AdCA-mIFN was injected once into the
tumour on the left leg. A regression of both the treated tumour on
the left leg and the untreated tumour on the opposite leg was
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Figure 5 Expression of NKG2D ligands on pancreatic cancer cell lines. (A) RT–PCR analyses of NKG2D ligands. Total RNA was extracted from cell lines
and after reverse transcription the mRNA of MICA, MICB, ULBP-1, ULBP-2 and ULBP-3 was detected by PCR. (B) Flow cytometric analysis of MICA and
MICB. Cells were incubated with anti-human MICA/B monoclonal antibody (filled curve) or isotype control antibody (open curve), and flow cytometry was
carried out using a FACScan system.
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IFN did not affect the growth of tumours on the right leg. When we
pretreated the mice with an anti-asialo GM1 antibody to purge NK
cells, the mouse IFN-a-induced antitumour effect was cancelled
(Figure 8A, right panel).
As another model of distant metastasis, we injected AsPC-1 cells
into the left leg and the peritoneal cavity, and again, when tumour
mass was established on the left leg, 1 10
8PFU of adenovirus was
injected once into the tumour. The treatment with AdCA-mIFN
resulted in a profound and statistically significant improvement
(Po0.01) in the survival of the treated mice as compared with
AxCA-IFN and AdCA-AP (Figure 8B). All of the dead animals were
confirmed to have disseminated tumours in the peritoneal cavity.
These data demonstrated that the antitumour effect of a local IFN-
a gene therapy is not limited to a locally injected tumour site, but
that it can induce a systemic immunity against pancreatic cancer
cells.
DISCUSSION
It has been reported that the modes of antitumour responses from
IFN-a gene therapy manifested three aspects: direct antiprolifera-
tive effect (Zhang et al, 1996; Ahmed et al, 1999, 2001; Iqbal
Ahmed et al, 2001; Demers et al, 2002), stimulation of cytotoxic T
cells (Coleman et al, 1998; Horton et al, 1999; Li et al, 2001) and
antiangiogenesis activity (Indraccolo et al, 2002a,b). Although
others highlighted each antitumour mechanism in the basic studies
of IFN-a gene therapy, in this study we demonstrated that
intratumoral injection of the IFN-a adenovirus could effectively
suppress xenograft tumours of pancreatic cancer due to the dual
mechanisms of antitumour activities: the direct regional apoptosis
induction and the systemic immunological effect at least through
NK cell activation. Furthermore, the IFN-a protein concentration
was markedly increased in the injected subcutaneous tumour, but
leakage into the serum was minimal, suggesting the safety of
intratumoral injection of an IFN-a adenovirus. Qin et al (2001)
also reported that IFN-b gene therapy induced direct antitumour
activity and an immunological effect of NK cells against human
glioblastoma. However, IFN-b protein showed less of an anti-
proliferative effect against pancreatic cancer cells than did IFN-a
(unpublished data). Although the type 1 IFNs, the a-family
and b, share receptor components, they were observed to have
differences in their receptor binding and signalling (Abramovich
et al, 1994a,b), which may explain their different antitumour
activities.
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Figure 6 Immunological antitumour effect of mouse IFN-a gene transduction into AsPC-1 subcutaneous tumours in nude mice. (A) Growth inhibition of
subcutaneous tumour injected with AxCA-IFN and AdCA-mIFN. When the AsPC-1 subcutaneous tumour was established on the left leg, 1.0 10
8PFU of
viral solution was injected once into the tumour. Tumour size in each mouse (AdCA-mIFN: n¼6; AxCA-IFN: n¼6; AdCA-AP: n¼4) was plotted on the
days indicated. (B) NK cell activity of AdCA-mIFN-injected mice. NK cells were harvested from the spleens of treated animals 14 days after the intratumoral
injection of adenoviruses.
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sIn this study, we injected the IFN-a-expressing vector locally
to the tumour mass. In pancreatic cancer, such a regional therapy
is particularly relevant, because locally advanced cases are
surgically unresectable but can be accessible by laparoscopy-
mediated injection or ultrasound- or CT-guided percutaneous
injection. In a clinical setting, IFN-a gene therapy could exert
tumour suppressive effects based both on direct cytotoxicity
and indirect immunological antitumour activities, the combination
of which is expected to be highly efficacious against locally
advanced pancreatic cancer. Even though some pancreatic cancer
cells are resistant to the direct antiproliferation and cell death-
inducing activities of IFN-a, such resistant cancer cells could be
suppressed by the activation of the innate immune system, as
shown in this study. The NK cells can be activated locally in the
tumour and/or activated systemically through immune organs
such as the spleen (Qin et al, 2001). The latter can result from
vector dissemination into the spleen or the circulation of a low
level of IFN-a that is released by the vector-transduced tumour
cells. Pancreatic cancer cells might be an effective target of
activated NK cells, because the cancer cell lines express a variety
of NKG2D ligands as shown in Figure 5. Moreover, cytokine-
mediated activation of a host adaptive immune system may also
contribute to the mounting of a systemic immunity against
pancreatic cancer in this direct local IFN-a gene therapy, although
this effect could not be evaluated in our nude mice study. In
addition to locally advanced cases, distant metastasis at the liver
and in the peritoneal cavity may be a clinical target of local IFN-a
gene therapy.
With respect to the safety of the therapy, it is noteworthy that
the IFN-a gene transfer showed very limited antiproliferative
effects on normal cells such as hepatocytes and vascular
endothelial cells (Hatanaka et al, 2004), although their mechanisms
are still not fully understood. In addition, there was much
difference in the IFN-a protein concentration between a vector-
injected tumour tissue and the serum. In fact, although a mild
elevation of hepatic enzymes was observed at day 5 only when a
relatively high dose (2.5 10
8PFU) of IFN-a adenovirus was
injected into the tumours (Table 1), the elevation returned to a
normal range at day 11. Therefore, we expect that the toxicity of
local IFN-a gene therapy is tolerable in human clinical trials,
although more preclinical toxicity study using larger animals such
as non-human primates will be required. One additional potential
advantage of gene therapy technology is that we can design and
preinstall safety devices to control transgene effects, such as
suicidal gene, regulatable promoter or a Cre/loxP-mediated shut-
off system of IFN-a expression in vivo (Suzuki et al, 2003). In sum,
our preclinical study suggests that the regional adenovirus-
mediated gene transfer of IFN-a is one of the promising new
approaches to the pancreatic cancer. The strategy may deserve an
evaluation in a future clinical trial for this highly intractable
cancer.
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Figure 7 Histological and immunohistochemical analyses of AsPC-1 tumours treated with AxCA-IFN and AdCA-mIFN. At 5 days after the injection of
1.0 10
8PFU of viral solutions, the subcutaneous tumours were fixed with formalin for haematoxylin-eosin (HE) staining, immunohistochemistry with anti-
asialo GM1 antibody or TUNEL staining ( 200). Fresh tumour samples were embedded in OCT compound and sections were fixed with 4%
paraformaldehyde and then processed for immunohistochemistry with anti-mouse CD31 antibody ( 200).
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Figure 8 Suppression of tumours at distant sites by the intratumoral injection of AdCA-mIFN into subcutaneous xenografts. (A) Suppression of
contralateral subcutaneous tumours. The AsPC-1 cells were injected subcutaneously into both legs, and then 1.0 10
8PFU of viral solution was injected
once into the left tumour (n¼6). The data (mean7s.d.) were expressed as the relative tumour volume, which is the tumour volume on the days indicated,
divided by that on day 0. For NK cell depletion experiments, mice were treated with intraperitoneal (i.p.) injection of anti-asialo GM1 antibody for four times.
*Po0.05 for tumours on the left legs injected with AdCA-mIFN in the presence or absence of anti-asialo GM1 antibody, **Po0.05 for tumours on the right
legs untreated with AdCA-mIFN in the presence or absence of anti-asialo GM1antibody. (B) Suppression of peritoneal dissemination. When the AsPC-1
subcutaneous tumour was established on the left leg, 1 10
6 (left panel) or 5 10
6 cells (right panel) of AsPC-1 cell suspensions were injected into the
peritoneal cavity, and 1 day later, 1.0 10
8PFU of viral solution was injected once into the subcutaneous tumour. (Left panel) AdCA-mIFN: n¼10; AxCA-
IFN: n¼10; AdCA-AP: n¼10. (Right panel) AdCA-mIFN: n¼11; AxCA-IFN: n¼9; AdCA-AP: n¼9. *
,**Po0.01 for survival rate of AdCA-mIFN-treated
mice vs AxCA-IFN- and AdCA-AP-treated mice.
Table 1 Evaluation of selected serum chemistries 5 days after intratumoral injection of AdCA-mIFN
AdCA-mIFN AdCA-AP No treatment
Dose (PFU):  10
8 2.5 1.0 0.25 2.5 —
Mouse IFN concentration
Tumour (pgg
 1):  10
3 252.37292.2 53.0730.0 14.3713.4 1.470.6 0.870.2
Serum (pgml
 1):  10
3 1.770.9 0.370.1 0.370.2 0.270.1 0.270.1
Albumin (gdl
 1) 2.870.3 2.970.4 2.870.4 2.770.1 2.970.3
Alk. phos. (IUl
 1) 231771 186729 199744 186721 218781
Amylase (Ul
 1) 1391073932 1659576937 177907453 148507353 1026973922
BUN (mgdl
 1) 19.171.6 23.676.4 21.272.4 22.771.3 23.974.0
Creatinine (mgdl
 1) 0.087 0.02 0.097 0.02 0.170.01 0.0970.02 0.1170.03
LDH (IUl
 1) 3797 69 316768 5607244 4867252 3687216
AST (IUl
 1) 12674 101742 93734 68717 70723
ALT (IUl
 1)5 4 732 28742 5 771 8 710 1975
T. bil. (mgdl
 1) 0.0570.01 0.0470.01 0.0570.01 0.0670.01 0.0470.01
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